Association of tumor mutational burden with outcomes of patients receiving ICIs for diverse advanced cancers

There are few studies assessing the association of tumor mutational burden (TMB) with outcomes of patients with diverse advanced cancers. A retrospective cohort study of 674 patients receiving first- or second-line immune checkpoint inhibitors (ICIs) for 8 distinct advanced cancers found that TMB-high cancers were significantly associated with longer overall survival than TMB-low cancers. These findings were robust to the ICI administered and remained significant after adjustment for programmed cell death-ligand 1 and microsatellite instability status. The authors conclude that patients identified as TMB-high should be considered for ICI therapy.